Search
Grifols SA
GRFSAdd to Watchlist
7.310USD
-0.090-1.22%
Close 09-18 16:00（ET）
1.88BMarket Cap
9.40P/E TTM
More Details of Grifols SA Company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Grifols SA Profile
Ticker SymbolGRFS
Company nameGrifols SA
IPO dateMay 17, 2006
CEOAbia (Jose Ignacio)
Number of employees23833
Security typeDepository Receipt
Fiscal year-endMay 17
AddressParque Empresarial Can Sant Joan
CitySANT CUGAT DEL VALLES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySpain
Postal code08174
Phone34935710000
Websitehttps://www.grifols.com/
Ticker SymbolGRFS
IPO dateMay 17, 2006
CEOAbia (Jose Ignacio)
Company Executives of Grifols SA
Name
Name/Position
Position
Shareholding
Change
Mr. Enrique De La Torre
Mr. Enrique De La Torre
Chief Compliance Officer
Chief Compliance Officer
--
--
Mr. Roland Wandeler, Ph.D.
Mr. Roland Wandeler, Ph.D.
President - Biopharma
President - Biopharma
--
--
Ms. Irene Roche Font
Ms. Irene Roche Font
Vice President - Accounting and Financial Services
Vice President - Accounting and Financial Services
--
--
Ms. Montseratt Ribas Loveras
Ms. Montseratt Ribas Loveras
Chief Communication and Reputation Officer
Chief Communication and Reputation Officer
--
--
Dr. Ester Masllorens Llinas
Dr. Ester Masllorens Llinas
Independent Director
Independent Director
--
--
Ms. Joanna Susan Le Couilliard
Ms. Joanna Susan Le Couilliard
Independent Director
Independent Director
--
--
Mr. Tomas Daga Gelabert
Mr. Tomas Daga Gelabert
Other External Director
Other External Director
--
--
Mr. Raimon Grifols Roura
Mr. Raimon Grifols Roura
Vice Chairman of the Board, Proprietary Director
Vice Chairman of the Board, Proprietary Director
--
--
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Assistant Secretary of the Board of Directors
Non-Member Assistant Secretary of the Board of Directors
--
--
Mr. Ignacio Ramal Subira
Mr. Ignacio Ramal Subira
Chief Internal Audit & Enterprise Risk Management
Chief Internal Audit & Enterprise Risk Management
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Enrique De La Torre
Mr. Enrique De La Torre
Chief Compliance Officer
Chief Compliance Officer
--
--
Mr. Roland Wandeler, Ph.D.
Mr. Roland Wandeler, Ph.D.
President - Biopharma
President - Biopharma
--
--
Ms. Irene Roche Font
Ms. Irene Roche Font
Vice President - Accounting and Financial Services
Vice President - Accounting and Financial Services
--
--
Ms. Montseratt Ribas Loveras
Ms. Montseratt Ribas Loveras
Chief Communication and Reputation Officer
Chief Communication and Reputation Officer
--
--
Dr. Ester Masllorens Llinas
Dr. Ester Masllorens Llinas
Independent Director
Independent Director
--
--
Ms. Joanna Susan Le Couilliard
Ms. Joanna Susan Le Couilliard
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Grifols SA?
The top five shareholders of Grifols SA are: Mr. Enrique De La Torre
How many institutions hold shares of Grifols SA (GRFS)?
As of 2026Q1, 346 institutions hold shares of Grifols SA, with a combined market value of approximately 148.94M, accounting for 57.68% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -8688154.00.